

2018 Irritable Bowel Syndrome Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/2303D887240EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2303D887240EN

Abstracts

Irritable bowel syndrome (IBS) is a chronic gastrointestinal and functional bowel disorder that affects around 10-15% of population during their lifetime. It causes abdominal pain, cramps, bloating, diarrhea or constipation. The drug market for the disease is estimated to be around \$1.5 billion.

Over 50 companies and universities are focusing on developing treatment options for Irritable Bowel Syndrome.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Irritable Bowel Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Irritable Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Irritable Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2 IRRITABLE BOWEL SYNDROME PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Irritable Bowel Syndrome Pipeline Snapshot

2.3 Irritable Bowel Syndrome Pipeline by Phase

2.4 Irritable Bowel Syndrome Pipeline by Company

2.5 Irritable Bowel Syndrome Pipeline by Mechanism of Action

3 IRRITABLE BOWEL SYNDROME- COMPANY WISE PIPELINE ANALYSIS

4D Pharma PLC

Alfa Wassermann SpA

Allergan

Aptevo Therapeutics Inc

Ardelyx Inc

Assembly Biosciences

Astellas Pharma Inc

Axim Biotechnologies

CinRx Pharma LLC

ConSynance Therapeutics

Cosmo Pharmaceuticals NV

Dong-A ST Co

Enterome Bioscience SA

GlaxoSmithKline

ImmuneBiotech AB

Innovative Med Concepts LLC

Ironwood Pharmaceuticals

LTT Bio-Pharma Co

Napo Pharmaceuticals

Nobilis Therapeutics

Orphomed Inc

Outpost Medicine

Palo BioFarma SL
Pfizer Inc
RaQualia Pharma Inc
RedHill Biopharma
Scythian Biosciences Corp
Seldar Pharma Inc
SK Biopharmaceuticals
Sumitomo Dainippon Pharma
Synergy Pharmaceuticals
Synthetic Biologics Inc
Tillotts Pharma
- Velicept Therapeutics Inc
Vitality Biopharma

4 IRRITABLE BOWEL SYNDROME R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN IRRITABLE BOWEL SYNDROME PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018

Figure 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018
- Table 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018
- Table 3: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
- Table 4: 4D Pharma PLC Irritable Bowel Syndrome pipeline, May 2018
- Table 5: Alfa Wassermann SpA Irritable Bowel Syndrome pipeline, May 2018
- Table 6: Allergan Irritable Bowel Syndrome pipeline, May 2018
- Table 7: Aptevo Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 8: Ardelyx Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 9: Assembly Biosciences Irritable Bowel Syndrome pipeline, May 2018
- Table 10: Astellas Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 11: Axim Biotechnologies Irritable Bowel Syndrome pipeline, May 2018
- Table 12: CinRx Pharma LLC Irritable Bowel Syndrome pipeline, May 2018
- Table 13: ConSynance Therapeutics Irritable Bowel Syndrome pipeline, May 2018
- Table 14: Cosmo Pharmaceuticals NV Irritable Bowel Syndrome pipeline, May 2018
- Table 15: Dong-A ST Co Irritable Bowel Syndrome pipeline, May 2018
- Table 16: Enterome Bioscience SA Irritable Bowel Syndrome pipeline, May 2018
- Table 17: GlaxoSmithKline Irritable Bowel Syndrome pipeline, May 2018
- Table 18: ImmuneBiotech AB Irritable Bowel Syndrome pipeline, May 2018
- Table 19: Innovative Med Concepts LLC Irritable Bowel Syndrome pipeline, May 2018
- Table 20: Ironwood Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
- Table 21: LTT Bio-Pharma Co Irritable Bowel Syndrome pipeline, May 2018
- Table 22: Napo Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
- Table 23: Nobilis Therapeutics Irritable Bowel Syndrome pipeline, May 2018
- Table 24: Orphomed Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 25: Outpost Medicine Irritable Bowel Syndrome pipeline, May 2018
- Table 26: Palo BioFarma SL Irritable Bowel Syndrome pipeline, May 2018
- Table 27: Pfizer Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 28: RaQualia Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 29: RedHill Biopharma Irritable Bowel Syndrome pipeline, May 2018
- Table 30: Scythian Biosciences Corp Irritable Bowel Syndrome pipeline, May 2018
- Table 31: Seldar Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
- Table 32: SK Biopharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
- Table 33: Sumitomo Dainippon Pharma Irritable Bowel Syndrome pipeline, May 2018
- Table 34: Synergy Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
- Table 35: Synthetic Biologics Inc Irritable Bowel Syndrome pipeline, May 2018

Table 36: Tillotts Pharma Irritable Bowel Syndrome pipeline, May 2018

Table 37: Velicept Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018

Table 38: Vitality Biopharma Irritable Bowel Syndrome pipeline, May 2018

I would like to order

Product name: 2018 Irritable Bowel Syndrome Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/2303D887240EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2303D887240EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970